Skip to main content
Top
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma

Authors: Na Liu, Rui-Xue Cui, Qing-Mei He, Bi-Jun Huang, Ying Sun, Dan Xie, Jing Zeng, Hui-Yun Wang, Jun Ma

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

Dicer11 plays an important role in generation of microRNA and is dysregulated in a variety of human cancers. The purpose of this study was to evaluate Dicer11 expression and its prognostic value in nasopharyngeal carcinoma (NPC). The protein expression of Dicer1 was examined by immunohistochemistry in 276 NPC specimens, and the mRNA levels of Dicer1 were analyzed by qRT-PCR in 56 NPC and 11 nasopharyngitis tissues. Cox regression analysis was used to identify independent prognostic factors, and a prognostic score model was constructed for survival prediction. Expression of Dicer1 was downregulated in NPC tissues at both the mRNA and the protein levels, and there was a notable positive correlation between the expression levels of Dicer1 mRNA and protein. Low Dicer1 expression was positively correlated with distant metastasis (P < 0.01) and death (P = 0.01). In addition, low expression of Dicer1 was significantly associated with poorer overall survival (HR, 2.32; 95 % CI 1.30–4.14; P < 0.01) and poorer distant metastasis-free survival (HR, 2.56; 95 % CI 1.39–4.74; P < 0.01). Furthermore, multivariate analysis showed that low expression of Dicer1 and tumor-node-metastasis (TNM) stage was independent prognostic indicators for NPC patients. A prognostic score model combining the Dicer1 expression and TNM stage had a better prognostic value than the TNM stage alone model or Dicer1 expression alone model (P < 0.05). Dicer1 was downregulated in NPC tissues at both the mRNA and the protein levels, and low expression of Dicer1 could be served as novel prognostic biomarker for NPC patients.
Literature
1.
go back to reference Curado MP, Edwards BK. Cancer incidence in five continents. Vol IX. IARC Scientific Pub. No. 160. Lyon: IARC; 2007. Curado MP, Edwards BK. Cancer incidence in five continents. Vol IX. IARC Scientific Pub. No. 160. Lyon: IARC; 2007.
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
go back to reference Edge SB, Byrd DR. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Edge SB, Byrd DR. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
4.
go back to reference Au JS, Law CK, Foo W, Lau WH. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys. 2003;56:413–26.PubMedCrossRef Au JS, Law CK, Foo W, Lau WH. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements. Int J Radiat Oncol Biol Phys. 2003;56:413–26.PubMedCrossRef
5.
go back to reference Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73:1326–34.PubMedCrossRef Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73:1326–34.PubMedCrossRef
6.
go back to reference Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414–8.PubMedCrossRef Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414–8.PubMedCrossRef
7.
go back to reference Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest. 2007;25:315–21.PubMedCrossRef Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest. 2007;25:315–21.PubMedCrossRef
8.
go back to reference Lv X, Xiang YQ, Cao SM, et al. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment. Head Neck. 2011;33:780–5.PubMedCrossRef Lv X, Xiang YQ, Cao SM, et al. Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: more distant metastases and shorter overall survival after treatment. Head Neck. 2011;33:780–5.PubMedCrossRef
9.
go back to reference Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363–6.PubMedCrossRef Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363–6.PubMedCrossRef
10.
go back to reference Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 2005;579:5822–9.PubMedCrossRef Hammond SM. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 2005;579:5822–9.PubMedCrossRef
11.
go back to reference Merritt WM, Lin YG, Han LY, et al. Dicer1, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008;359:2641–50.PubMedCrossRef Merritt WM, Lin YG, Han LY, et al. Dicer1, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008;359:2641–50.PubMedCrossRef
12.
go back to reference Flavin RJ, Smyth PC, Finn SP, et al. Altered eIF6 and Dicer1 expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008;21:676–84.PubMedCrossRef Flavin RJ, Smyth PC, Finn SP, et al. Altered eIF6 and Dicer1 expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol. 2008;21:676–84.PubMedCrossRef
13.
go back to reference Faggad A, Budczies J, Tchernitsa O, et al. Prognostic significance of Dicer1 expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol. 2010;220:382–91.PubMed Faggad A, Budczies J, Tchernitsa O, et al. Prognostic significance of Dicer1 expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol. 2010;220:382–91.PubMed
14.
go back to reference Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer1 associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96:111–5.PubMedCrossRef Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer1 associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96:111–5.PubMedCrossRef
15.
go back to reference Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer1 in precursor lesions of lung adenocarcinoma. Cancer Res. 2007;67:2345–50.PubMedCrossRef Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer1 in precursor lesions of lung adenocarcinoma. Cancer Res. 2007;67:2345–50.PubMedCrossRef
16.
go back to reference Sugito N, Ishiguro H, Kuwabara Y, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res. 2006;12:7322–8.PubMedCrossRef Sugito N, Ishiguro H, Kuwabara Y, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res. 2006;12:7322–8.PubMedCrossRef
17.
go back to reference Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of Dicer1, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol. 2006;169:1812–20.PubMedCrossRef Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of Dicer1, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol. 2006;169:1812–20.PubMedCrossRef
18.
go back to reference Grelier G, Voirin N, Ay AS, et al. Prognostic value of Dicer1 expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009;101:673–83.PubMedCrossRef Grelier G, Voirin N, Ay AS, et al. Prognostic value of Dicer1 expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009;101:673–83.PubMedCrossRef
19.
go back to reference Zighelboim I, Reinhart AJ, Gao F, et al. Dicer1 expression and outcomes in endometrioid endometrial adenocarcinoma. Cancer. 2011;117:1446–53.PubMedCrossRef Zighelboim I, Reinhart AJ, Gao F, et al. Dicer1 expression and outcomes in endometrioid endometrial adenocarcinoma. Cancer. 2011;117:1446–53.PubMedCrossRef
20.
go back to reference Faber C, Horst D, Hlubek F, Kirchner T. Overexpression of Dicer1 predicts poor survival in colorectal cancer. Eur J Cancer. 2011;47:1414–9.PubMedCrossRef Faber C, Horst D, Hlubek F, Kirchner T. Overexpression of Dicer1 predicts poor survival in colorectal cancer. Eur J Cancer. 2011;47:1414–9.PubMedCrossRef
21.
go back to reference Ma J, Liu L, Tang L, et al. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007;13:1445–52.PubMedCrossRef Ma J, Liu L, Tang L, et al. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007;13:1445–52.PubMedCrossRef
22.
go back to reference Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71:1356–64.PubMedCrossRef Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71:1356–64.PubMedCrossRef
23.
go back to reference Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:2038–44.PubMedCrossRef Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:2038–44.PubMedCrossRef
24.
go back to reference Li W, Yu CP, Xia JT, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15:1393–9.PubMedCrossRef Li W, Yu CP, Xia JT, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15:1393–9.PubMedCrossRef
25.
go back to reference Liao WT, Wang X, Xu LH, et al. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer. 2009;115:1507–17.PubMedCrossRef Liao WT, Wang X, Xu LH, et al. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer. 2009;115:1507–17.PubMedCrossRef
26.
go back to reference Korbler T, Grskovic M, Dominis M. Antica M (2004) A simple method for RNA isolation from formalin-fixed and paraffin-embedded lymphatic tissues. Exp Mol Pathol. 2003;74:336–40.PubMedCrossRef Korbler T, Grskovic M, Dominis M. Antica M (2004) A simple method for RNA isolation from formalin-fixed and paraffin-embedded lymphatic tissues. Exp Mol Pathol. 2003;74:336–40.PubMedCrossRef
27.
go back to reference Marshall OJ. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics. 2004;20:2471–2.PubMedCrossRef Marshall OJ. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics. 2004;20:2471–2.PubMedCrossRef
28.
go back to reference Yang HI, Yuen MF, Chan HLY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of the predictive score. Lancet Oncol. 2011;12:568–74.PubMedCrossRef Yang HI, Yuen MF, Chan HLY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of the predictive score. Lancet Oncol. 2011;12:568–74.PubMedCrossRef
29.
go back to reference Liu N, Chen NY, Cui RX, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13:633–41.PubMedCrossRef Liu N, Chen NY, Cui RX, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13:633–41.PubMedCrossRef
30.
go back to reference Sengupta S, Den Boon JA, Chen IH, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA. 2008;105:5874–8.PubMedCrossRef Sengupta S, Den Boon JA, Chen IH, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA. 2008;105:5874–8.PubMedCrossRef
31.
go back to reference Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100:1002–11.PubMedCrossRef Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100:1002–11.PubMedCrossRef
32.
go back to reference Cheng C, Fu X, Alves P, Gerstein M. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol. 2009;10:R90.PubMedCrossRef Cheng C, Fu X, Alves P, Gerstein M. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol. 2009;10:R90.PubMedCrossRef
33.
go back to reference Guo X, Liao Q, Chen P, et al. The microRNA-processing enzymes: Drosha and Dicer1 can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012;138:49–56.PubMedCrossRef Guo X, Liao Q, Chen P, et al. The microRNA-processing enzymes: Drosha and Dicer1 can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012;138:49–56.PubMedCrossRef
34.
go back to reference Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661–8.PubMedCrossRef Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661–8.PubMedCrossRef
35.
go back to reference Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004;101:300–6.PubMedCrossRef Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer. 2004;101:300–6.PubMedCrossRef
36.
go back to reference Han L, Zhang A, Zhou X, et al. Downregulation of Dicer1 enhances tumor cell proliferation and invasion. Int J Oncol. 2010;37:299–305.PubMed Han L, Zhang A, Zhou X, et al. Downregulation of Dicer1 enhances tumor cell proliferation and invasion. Int J Oncol. 2010;37:299–305.PubMed
37.
go back to reference Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting Dicer1 for metastasis control. Cell. 2010;141:1195–207.PubMedCrossRef Martello G, Rosato A, Ferrari F, et al. A MicroRNA targeting Dicer1 for metastasis control. Cell. 2010;141:1195–207.PubMedCrossRef
38.
go back to reference Shao JY, Huang XM, Yu XJ, et al. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Anticancer Res. 2001;21:3021–9.PubMed Shao JY, Huang XM, Yu XJ, et al. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Anticancer Res. 2001;21:3021–9.PubMed
39.
go back to reference Cheng R, Lo K, Huang D, Tsao S. Loss of heterozygosity on chromosome 14 in primary nasopharyngeal carcinoma. Int J Oncol. 1997;10:1047–50.PubMed Cheng R, Lo K, Huang D, Tsao S. Loss of heterozygosity on chromosome 14 in primary nasopharyngeal carcinoma. Int J Oncol. 1997;10:1047–50.PubMed
Metadata
Title
Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma
Authors
Na Liu
Rui-Xue Cui
Qing-Mei He
Bi-Jun Huang
Ying Sun
Dan Xie
Jing Zeng
Hui-Yun Wang
Jun Ma
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0360-3

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine